J. Lipid Res. Did you know there is a large type edition? Click here.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on August 1, 2007

Papers In Press, published online ahead of print May 24, 2007
J. Lipid Res., doi:10.1194/jlr.M700108-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M700108-JLR200v1
48/8/1763    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van der Hoogt, C. C.
Right arrow Articles by Rensen, P. C. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van der Hoogt, C. C.
Right arrow Articles by Rensen, P. C. N.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on March 1, 2007
Revised on May 18, 2007
Accepted on May 24, 2007

Fenofibrate increases HDL cholesterol by reducing cholesteryl ester transfer protein expression

Caroline C. Van der Hoogt, Willeke De Haan, Marit Westerterp, Menno Hoekstra, Geesje M. Dallinga-Thie, Johannes A. Romijn, Hans M..G. Princen, J. Wouter Jukema, Louis M. Havekes, and Patrick C. N. Rensen

Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, Zuid-Holland 2300 RC

Corresponding Author: P.C.N.Rensen{at}lumc.nl

In addition to efficiently lowering VLDL-triglycerides (TG), fenofibrate increases HDL-cholesterol levels in humans. We investigated whether the fenofibrate-induced increase in HDL-cholesterol is dependent on the expression of the cholesteryl ester transfer protein (CETP). Hereto, APOE*3-Leiden (E3L) transgenic mice without and with the human CETP transgene, under control of its natural regulatory flanking regions, were fed a Western-type diet with or without fenofibrate. Fenofibrate (0.04% in the diet) decreased plasma TG in E3L and E3L.CETP mice (-59% and -60%; P<0.001), caused by a strong reduction in VLDL. Whereas fenofibrate did not affect HDL-cholesterol in E3L mice, fenofibrate dose-dependently increased HDL-cholesterol in E3L.CETP mice (up to +91%). Fenofibrate did not affect the turnover of HDL-CE, indicating that fenofibrate causes a higher steady-state HDL-cholesterol level without altering the HDL-cholesterol flux through plasma. Analysis of the hepatic gene expression profile showed that fenofibrate did not differentially affect the main players in HDL metabolism in E3L.CETP mice as compared to E3L mice. However, in E3L.CETP mice, fenofibrate reduced hepatic CETP mRNA (-72%; P<0.01) as well as the CE transfer activity in plasma (-73%; P<0.01). We conclude that fenofibrate increases HDL-cholesterol by reducing the CETP-dependent transfer of cholesterol from HDL to (V)LDL, as related to lower hepatic CETP expression and a reduced plasma (V)LDL pool.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. W.A. van der Hoorn, W. de Haan, J. F.P. Berbee, L. M. Havekes, J. W. Jukema, P. C.N. Rensen, and H. M.G. Princen
Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice
Arterioscler. Thromb. Vasc. Biol., November 1, 2008; 28(11): 2016 - 2022.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
W. de Haan, J. de Vries-van der Weij, J. W.A. van der Hoorn, T. Gautier, C. C. van der Hoogt, M. Westerterp, J. A. Romijn, J. W. Jukema, L. M. Havekes, H. M.G. Princen, et al.
Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin
Circulation, May 13, 2008; 117(19): 2515 - 2522.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.